Literature DB >> 1810323

Low thymosin alpha-1 concentrations in patients chronically infected with the hepatitis B virus.

K E Sherman1, C C Jones, A L Goldstein, P H Naylor.   

Abstract

Serum concentrations of thymosin alpha-1 (TA-1), an immunoregulatory peptide, were assayed in patients with chronic hepatitis B infection and volunteer blood donor controls. Coded samples were tested using a radioimmunoassay. The TA-1 concentrations in HBsAg-positive patients averaged 1555 pg/ml, whereas in the control group, the mean TA-1 in serum was 2159 pg/ml (P less than 0.001). Similar results were found for age- and sex-matched pairs. The TA-1 concentration was not associated with HBe antigen/antibody status or with values of liver-associated enzymes. Analysis of T-cell subsets in nine HBsAg carriers revealed significantly decreased CD4 (helper)-cells, both in absolute numbers and as the percentage of total lymphocytes present. These data suggest that individuals with chronic hepatitis B infection have a relative deficiency of the immunomodulatory peptide TA-1, which may contribute to the characteristics of the resultant T-cell population.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1810323     DOI: 10.1089/vim.1991.4.195

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  5 in total

1.  Quantitative analysis of thymosin alpha1 in human serum by LC-MS/MS.

Authors:  C W Tuthill; A Rudolph; Y Li; B Tan; T J Fitzgerald; S R Beck; Y X Li
Journal:  AAPS PharmSciTech       Date:  2000-05-14       Impact factor: 3.246

2.  Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases.

Authors:  F Pica; M S Chimenti; R Gaziano; C Buè; I A Casalinuovo; P Triggianese; P Conigliaro; D Di Carlo; V Cordero; G Adorno; A Volpi; R Perricone; E Garaci
Journal:  Clin Exp Immunol       Date:  2016-08-01       Impact factor: 4.330

3.  A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B.

Authors:  C Zavaglia; R Severini; C Tinelli; J S Franzone; A Airoldi; S Tempini; G Bettale; G Ideo
Journal:  Dig Dis Sci       Date:  2000-04       Impact factor: 3.199

4.  Potential Role of Thymosin-alpha1 Adjuvant Therapy for Glioblastoma.

Authors:  Arno Sungarian; Deus Cielo; Prakash Sampath; Nathaniel Bowling; Peter Moskal; Jack R Wands; Suzanne M de la Monte
Journal:  J Oncol       Date:  2010-01-11       Impact factor: 4.375

5.  Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life.

Authors:  Fanwen Wang; Tingting Yu; Heng Zheng; Xingzhen Lao
Journal:  Sci Rep       Date:  2018-08-17       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.